Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia

Despite being considered “good-risk” acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Borthakur, Gautam, Cortes, Jorge E., Estey, Elihu E., Jabbour, Elias, Faderl, Stefan, O’Brien, Susan, Garcia-Manero, Guillermo, Kadia, Tapan Mahendra, Wang, Xuemei, Patel, Keyur, Luthra, Rajyalakshmi, Koller, Charles, Brandt, Mark, Ravandi, Farhad, Kantarjian, Hagop
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4431614/
https://ncbi.nlm.nih.gov/pubmed/24990142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23795
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky